Reaction
Acne Pustular reporting signals
As of the last recalculation, Acne Pustular appears in 809 FAERS reports alongside 14 co-occurring drug terms. The strongest observed disproportionality signal is PANITUMUMAB (PRR 83.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Panitumumab | 48 | 83.7 | 84.0 |
| Adapalene | 287 | 62.3 | 62.4 |
| Sulfur | 17 | 53.0 | 53.1 |
| Salicylic Acid | 95 | 52.2 | 52.3 |
| Minocycline | 8 | 17.8 | 17.8 |
| Tretinoin | 5 | 15.9 | 15.9 |
| Erlotinib | 5 | 13.4 | 13.4 |
| Erlotinib Hydrochloride | 6 | 12.4 | 12.4 |
| Ado-Trastuzumab Emtansine | 4 | 12.3 | 12.3 |
| Cetuximab | 12 | 10.0 | 10.0 |
| Isotretinoin | 18 | 9.6 | 9.6 |
| Gefitinib | 3 | 8.6 | 8.6 |
| Vemurafenib | 3 | 6.4 | 6.4 |
| Bimekizumab | 4 | 4.9 | 4.9 |